Santen submits NDA for levofloxacin 1.5%

Santen Pharmaceuticals Co. filed a New Drug Application with the FDAon Monday for levofloxacin 1.5%, the company's new ocular anti-infectivedrug.The larger concentration of Levofloxacin is a potent, broad-spectrumantibiotic. The company reports that Levofloxacin's higher solubility, atneutral pH, allows the drug to be formulated at a higher concentration thanother fluoroquinolones on the market.